TACE plus immunotherapy and bevacizumab for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of a liver-directed treatment (TACE) with two immunotherapy drugs and bevacizumab for patients with liver cancer that cannot be surgically removed but has not spread outside the liver. The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery.
- Your liver is working fairly well (Child-Pugh class A) and you are in good overall health (ECOG 0 or 1).
- You have not had immunotherapy or targeted therapy for liver cancer before.
- The cancer has not spread outside the liver (no metastasis) and is not in the main portal vein.
- You are between 18 and 75 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments for liver cancer that can be surgically removed. It adds immunotherapy drugs (Iparomlimab and Tuvonralimab, together called QL1706) and targeted therapy (Lenvatinib) to a procedure called TACE (chemoembolization) to see if this approach shrinks the tumor and lowers the chance of recurrence after surgery.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This trial tests a combination of two drugs (bevacizumab and adebrelimab) plus a special procedure called TACE-HAIC to treat advanced liver cancer that cannot be surgically removed. The goal is to see if this combination is safe and effective as a first-line treatment.
This trial tests a procedure called TACE combined with an immune-boosting step for people with liver cancer that cannot be surgically removed. The goal is to see if this combination can help control the tumor while you are already on systemic treatment.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver. It tests whether combining a TACE procedure with immunotherapy and anti-angiogenesis drugs can improve outcomes. You must not have had prior systemic therapy and must have received TACE in a specific time window around starting these drugs.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.